Determination of perospirone by liquid chromatography/electrospray mass spectrometry: application to a pharmacokinetic study in healthy Chinese volunteers.
Ning Ma,Wen-Ying Liu,Huan-De Li,Yun-Gui Zhu,Bi-Kui Zhang,Feng Wang,Rong-Hua Zhu,Da-Xiong Xiang
DOI: https://doi.org/10.1016/j.jchromb.2006.10.007
IF: 3.318
2007-01-01
Journal of Chromatography B
Abstract:Perospirone is a novel atypical antipsychotic with a unique combination of 5-HT1A receptor agonism as well as 5-HT2A and D2 receptor antagonism. A simple rapid and selective LC–MS method utilizing a single quadrupole mass spectrometer was developed and validated for the determination of perospirone hydrochloride in human plasma. N-hexane was used to extract perospirone hydrochloride and amlodipine benzenesulfonate (internal standard (IS)) from an alkaline plasma sample. LC separation was performed on a XTerra ® MS C18 column (100mm×2.1mm, i.d. 3.5μm) using methanol −10mM ammonium acetate (84:16, v/v) as a mobile phase. The quantification of target compounds was obtained by using a selected ion monitoring (SIM) at m/z 427.5 [M+H]+ for perospirone hydrochloride, and at m/z 431.4 [M+Na]+ for IS (amlodipine benzenesulfonate). Perospirone and IS eluted as sharp, symmetrical peaks with retention times of 3.11±0.01min and 4.15±0.2min, respectively. Calibration curves of perospirone hydrochloride in human plasma at concentrations ranging from 0.10 to 21.1ng/mL exhibited excellent linearity (r2=0.9997). The mean absolute recovery of the drug from plasma was more than 85%. Intra- and inter-day relative standard deviations were less than 6.43% and 11.9% for perospirone hydrochloride at the range from 0.32 to 10.6ng/mL. Stability characteristics of the drug-containing plasma were thoroughly evaluated to establish appropriate conditions to process, store and prepare for chromatographic analysis without inducing significant chemical degradation. The following pharmacokinetic parameters were elucidated after administering a single dose of 8mg perospirone hydrochloride. The area under the plasma concentration versus time curve from time 0 to 24h (AUC0–24) was 15.48±4.23μg/Lh; peak plasma concentration (Cmax) was 2.79±0.78μg/L; time to Cmax (Tmax) was 1.79±0.45h; and elimination half-life (t1/2) 6.78±1.38h. The described assay method showed acceptable precision, accuracy, linearity, stability, and specificity and can be used for pharmacokinetic studies, therapeutic drug monitoring, and drug abuse screening.
What problem does this paper attempt to address?